Inhibition of the MEK/MAPK signal transduction pathway strongly impairs the growth of Flt3-ITD cells [9]

American Journal of Hematology

Volumn 81, Issue 2, 2006, Pages 154-155

  Takahashi, Shinichiro ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 6,7 DIMETHOXY 2 PHENYLQUINOXALINE; CD135 ANTIGEN; CELL PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; CANCER INHIBITION; CELL GROWTH; DRUG TARGETING; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LETTER; LEUKEMIA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

BUTADIENES; CELL PROLIFERATION; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, B-CELL; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; NITRILES; TANDEM REPEAT SEQUENCES;

EID: 32144441169     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20520     Document Type: Letter

References (5)

1. Takahashi S, McConnell MJ, Harigae H, et al. The Flt3 internal tandem duplication mutant inhibits the function of transcriptional repressors by blocking interactions with SMRT. Blood 2004;103:4650-4658.
2. Milella M, Kornblau SM, Estrov Z, et al. Therapeutic targeting of the MEK/ MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 2001;108:851-859.
3. Staber PB, Linkesch W, Zauner D, et al. Common alterations in gene expression and increased proliferation in recurrent acute myeloid leukemia. Oncogene 200423:894-904.
4. George P, Bali P, Cohen P, et al. Cotreatment with 17-allylamino- demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Res 2004;64:3645-3652.
5. Giles FJ. Stopeck AT, Silverman LR, et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in paiients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 2003;102:795-801.